Wat dis say? Burning?
ty.
Do what I do - check notables - go to bottom quick scan up the bread to get the gist of what is going on - then slow check down the bread.
We have more than we know. afaik the marks on the neck were never discussed. Small things & details that are missed or seem irrelevant at the time are rediscovered and lead or link back to other things.
British Medical Journal (BMJ) has urged public health regulators and pharmaceutical companies to immediately release all raw data from COVID-19 vaccine trials for independent scrutiny
BATTLEFORWORLD.COM | January 22, 2022:
Today, The British Medical Journal (BMJ) has criticized COVID-19 vaccine manufacturers for “reaping vast profits without adequate independent scrutiny of their scientific claims” for their vaccines used during the pandemic.
http://www.battleforworld.com/2021/11/20/covid-19-where-does-it-end-part-5/#BritishMedicalJournal
Covid-19 vaccines and treatments: we must have raw data, now
Data should be fully and immediately available for public scrutiny
In the pages of The BMJ a decade ago, in the middle of a different pandemic, it came to light that governments around the world had spent billions stockpiling antivirals for influenza that had not been shown to reduce the risk of complications, hospital admissions, or death. The majority of trials that underpinned regulatory approval and government stockpiling of oseltamivir (Tamiflu) were sponsored by the manufacturer; most were unpublished, those that were published were ghostwritten by writers paid by the manufacturer, the people listed as principal authors lacked access to the raw data, and academics who requested access to the data for independent analysis were denied.
We are left with publications but no access to the underlying data on reasonable request. This is worrying for trial participants, researchers, clinicians, journal editors, policy makers, and the public. The journals that have published these primary studies may argue that they faced an awkward dilemma, caught between making the summary findings available quickly and upholding the best ethical values that support timely access to underlying data. In our view, there is no dilemma; the anonymised individual participant data from clinical trials must be made available for independent scrutiny.
https://www.bmj.com/content/376/bmj.o102